Filing search / Wave Life Sciences Ltd. / "Safety"

8-K

EX-99.2

WVE Wave Life Sciences Ltd.

4 Mar 25

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7:51am

Cohort 3 SAD Cohort 2 SAD Cohort 1 Trial Design Objective: Assess dose safety, tolerability, PK and PD Key measurements Primary: Safety … key objectives Safety and tolerability Pharmacokinetics Serum M-AAT levels October 16, 2024 Proof-of-mechanism disclosure on first two “ZZ” AATD

8-K

EX-99.1

WVE Wave Life Sciences Ltd.

4 Mar 25

Wave Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

7:51am

with overweight or obesity and assesses safety, tolerability, pharmacokinetics, biomarkers for target engagement, body weight and composition, and metabolic health … from INLIGHT in the second half of 2025, including safety, tolerability and biomarkers reflective of healthy weight loss. GalNAc-RNA Editing Programs

8-K

EX-99.1

WVE Wave Life Sciences Ltd.

13 Jan 25

Regulation FD Disclosure

2:00pm

-controlled study of ascending doses of WVE-007 Trial Design SAD Cohort 5 Objective: Assess dose safety, MAD Cohort 3 tolerability, PK and PD SAD Cohort … 4 Key measurements MAD Cohort 2 - Primary: Safety and Tolerability - Secondary: PK, Activin E SAD Cohort 3 - Exploratory PD: MAD Cohort 1 Body weight

8-K

EX-99.1

WVE Wave Life Sciences Ltd.

20 Nov 24

Regulation FD Disclosure

6:05am

3 Dose C Cohort 2 Dose B Cohort 1 200 mg Dose A Study key objectives Safety and tolerability Pharmacokinetics Serum M-AAT levels 10 HV: healthy … AAT from baseline and M-AAT protein: Observed as early as day 3 and through day 57 WVE-006 well tolerated with a favorable safety profile; all AEs mild

8-K

EX-99.1

jqu4whls

12 Nov 24

Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

7:35am

8-K

EX-99.1

8u57wgyw

30 Oct 24

Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs

5:13pm

8-K

EX-99.1

2x3619rm5kmytb6

16 Oct 24

Regulation FD Disclosure

8:34am

8-K

EX-99.1

xldkk3ibc

1 Oct 24

Regulation FD Disclosure

7:35am

424B5

55ywe nsap6p7y9z

27 Sep 24

Prospectus supplement for primary offering

6:09am

424B5

u3ouhdwm5a zf

24 Sep 24

Prospectus supplement for primary offering

5:16pm

8-K

EX-99.1

azwnxu7y4i

24 Sep 24

Regulation FD Disclosure

7:34am

8-K

EX-99.1

pdrv285 58ss4

8 Aug 24

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

7:37am

8-K

EX-99.2

shmrn9p

8 Aug 24

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

7:37am

8-K

EX-99.1

6lcrd3i l45prnuad0zp

25 Jun 24

Regulation FD Disclosure

7:36am

8-K

EX-99.1

4etxce unha25wsgy3

9 May 24

Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

7:37am